657 completed, 242 terminated, 171 recruiting, 122 unknown. 1386 Phase 1, 514 Phase 2.
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Engineered Dendritic Cell Vaccines for Multiple Myeloma DC vaccines - Multiple Myeloma or Plasmacytoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2027-06-30 | 2026-11-02 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART) Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma | Phase 1 | Not yet recruiting | University of Chicago | 32 | 2027-02-23 | 2026-10-22 |
| Regenerative Medicine for Joint Hypermobility and Instability Dextrose 20% Prolotherapy, Autologous Platelet-Rich Plasma, Doxycycline Hyclate Injectable (Investigational) - Ehlers-Danlos Syndrome Hypermobility Type (hEDS), Ehlers-Danlos Syndrome (EDS) | Phase 1 / Phase 2 | Not yet recruiting | Manhattan Pain Medicine, PLLC | 100 | 2027-01-15 | 2026-10-06 |
| Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT) TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Not yet recruiting | Tectonic Operating Company, Inc. | 20 | 2026-12-31 | 2026-10-15 |
| Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma CAR T cells - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-10-30 |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma CAR-T cells - Multiple Myeloma, Plasmacytoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2026-12-31 | 2026-11-02 |
| Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma Etentamig, Isatuximab, Bortezomib + Lenalidomide + Dexamethasone - Myeloma Multiple, Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Universitätsklinikum Hamburg-Eppendorf | 220 | 2026-12-01 | 2026-05-20 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma CAR-T cells, BCMA bispecific - Myeloma Multiple | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | 44 | 2026-12-01 | 2026-10-09 |
| Study to Establish Safety, Tolerability and Pharmacokinetics of NRL-1049 in Healthy Adult Participants Following Multiple-Dose Administration NRL-1049, Placebo - Cerebral Cavernous Malformation | Phase 1 | Not yet recruiting | Neurelis, Inc. | 40 | 2026-11-11 | 2026-10-30 |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma Mirdametinib, Sirolimus - Multiple Myeloma, Relapsed and/or Refractory Multiple Myeloma (RRMM) | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 54 | 2026-11-08 | 2026-11-03 |
| Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine - Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM) | Phase 1 | Recruiting | Weill Medical College of Cornell University | 32 | 2026-11-01 | 2026-10-26 |
| Phase 1a/b Study of GPRC5D CART Therapy in Relapsed/Refractory Multiple Myeloma and Light-chain Amyloidosis GPRC5D CART - Relapsed/Refractory Multiple Myeloma (RRMM), Light-Chain Amyloidosis | Phase 1 | Not yet recruiting | Hadassah Medical Organization | 160 | 2026-11-01 | 2026-10-20 |
| A Study of MBS314 for Injectionin Participants With Relapsed/Refractory Multiple Myeloma. MBS314 for Injection - Multiple Myeloma | Phase 1 / Phase 2 | Not yet recruiting | Beijing Mabworks Biotech Co., Ltd. | 78 | 2026-11-01 | 2026-11-03 |
| Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies aldesleukin, cyclophosphamide, fludarabine phosphate - Malignancy, Hematologic, Neoplasms, Hematologic | Phase 1 | Recruiting | National Cancer Institute (NCI) | 86 | 2026-10-28 | 2026-11-02 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment Belantamab mafodotin, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 20 | 2026-10-23 | 2026-05-27 |
| A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care Belantamab SC, Belantamab IV, Recombinant Human Hyaluronidase PH20 (rHuPH20) - Multiple Myeloma | Phase 1 | Not yet recruiting | GlaxoSmithKline | 22 | 2026-10-16 | 2026-08-03 |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma BP2202 - Relapsed/Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | BrightPath Biotherapeutics Co., Ltd. | 18 | 2026-10-01 | 2026-08-21 |
Showing 20 of 1386. Sign in to see all of them.
Multiple Myeloma (1192) · Lymphoma, Non-Hodgkin (243) · Leukemia, Lymphocytic, Chronic, B-Cell (237) · Lymphoma, Follicular (212) · Lymphoma, Mantle-Cell (211) · Waldenstrom Macroglobulinemia (211) · Lymphoma, B-Cell, Marginal Zone (199) · Lymphoma, Large B-Cell, Diffuse (194) · Lymphoma (184) · Recurrence (182) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (173) · Neoplasms, Plasma Cell (168) · Hodgkin Disease (164) · Burkitt Lymphoma (149) · Leukemia, Myeloid, Acute (140)
Hemic and Lymphatic Diseases (1386) · Cardiovascular Diseases (1380) · Vascular Diseases (1377) · Hemorrhagic Disorders (1374) · Hematologic Diseases (1356) · Neoplasms by Histologic Type (1339) · Immune System Diseases (1338) · Immunoproliferative Disorders (1335) · Blood Protein Disorders (1332) · Paraproteinemias (1327) · Lymphoproliferative Disorders (1325) · Neoplasms (1273) · Neoplasms, Plasma Cell (1176) · Lymphatic Diseases (445)
Dexamethasone (265) · Lenalidomide (140) · Bortezomib (133) · Cyclophosphamide (114) · Calcium Dobesilate (97) · pomalidomide (83) · carfilzomib (72) · Melphalan (68) · daratumumab (61) · fludarabine (57) · fludarabine phosphate (51) · Rituximab (47) · Filgrastim (38) · Peripheral Blood Stem Cell Transplantation (35) · dexamethasone acetate (34)
National Cancer Institute (NCI) (72) · Mayo Clinic (37) · Celgene (34) · M.D. Anderson Cancer Center (26) · Memorial Sloan Kettering Cancer Center (26) · GlaxoSmithKline (23) · AbbVie (21) · Fred Hutchinson Cancer Center (21) · Amgen (18) · City of Hope Medical Center (18) · Janssen Research & Development, LLC (17) · Novartis Pharmaceuticals (16) · Millennium Pharmaceuticals, Inc. (15) · Washington University School of Medicine (14) · Masonic Cancer Center, University of Minnesota (13)
United States (966) · China (159) · Spain (118) · France (106) · Australia (102) · Canada (91) · Germany (77) · Italy (71) · United Kingdom (68) · Japan (59) · South Korea (53) · Israel (42) · Netherlands (35) · Greece (31) · Belgium (27)
Paul Richardson, MD (6) · James R Berenson, MD (5)
PMID 34398557, PMID 36100310, PMID 37022569, PMID 28803351, PMID 32499241, PMID 34515338, PMID 37192741, PMID 19238148, PMID 26370838, PMID 26943915, PMID 27412889, PMID 31215818, PMID 31527168, PMID 33980831, PMID 36375120, PMID 37270762, PMID 37658205, PMID 40000533, PMID 40826257, PMID 41100731, PMID 41118600, PMID 42287565, PMID 10552943, PMID 10564685, PMID 10613347, PMID 10764422, PMID 12171484, PMID 12473574, PMID 12752100, PMID 14767498, PMID 15241836, PMID 15466934, PMID 15570084, PMID 15902208, PMID 15958804, PMID 16061911, PMID 17020988, PMID 17312328, PMID 17975015, PMID 18032762, PMID 18032763, PMID 18202410, PMID 18297527, PMID 18327587, PMID 18418404, PMID 18463792, PMID 18470481, PMID 18768528, PMID 18974373, PMID 19179301
2023 (37), P30CA015083 (17), 2019 (16), 2018 (10), 2016 (9), U01CA076576 (9), 2017 (8), P30CA006973 (8), P30CA016058 (8), 2015 (7), 2025 (7), P30CA015704 (7), P30CA022453 (7), P30CA033572 (7), U01CA069912 (7)